deltatrials
Recruiting PHASE1 INTERVENTIONAL 8-arm NCT06873659

SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects With Advanced Solid Tumors

Sponsor: Qurgen Inc.

Conditions Gastric Cancer Liver Cancer Solid Tumor
Interventions SON-DP
Updated 3 times since 2025 Last updated: Sep 1, 2025 Started: Feb 26, 2025 Primary completion: Apr 30, 2027 Completion: Nov 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06873659, this PHASE1 trial focuses on Gastric Cancer and Liver Cancer and remains actively recruiting participants. Sponsored by Qurgen Inc., it has been updated 3 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshotRecruiting~Jun 2025 – ~Oct 2025 · 4 months · monthly snapshotRecruiting~Oct 2025 – present · 8 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE1

  2. Jun 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

  3. Apr 2025 — Jun 2025 [monthly]

    Recruiting PHASE1

    First recorded

Feb 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Qurgen Inc.
Data source: Qurgen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations